We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cequent Files its First IND with FDA for a tkRNAi Drug Candidate, CEQ508

News   Nov 16, 2009

 
Cequent Files its First IND with FDA for a tkRNAi Drug Candidate, CEQ508
 
 
 

RELATED ARTICLES

New Biomarkers Detect 70% of Pancreatic Cancer, a Vast Improvement

News

A new approach to pancreatic cancer screening may help doctors detect the disease in people at high risk before it reaches more advanced and difficult-to treat stages.

READ MORE

Protein Interactions Shed Light on Ebola Virus Replication

News

Researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE